Clinical trials for negative symptoms - Emerging directions and unresolved issues

Schizophrenia Research

Volumn 150, Issue 2-3, 2013, Pages 327-

  Marder, Stephen R ^a   Rabinowitz, Jonathan ^b   Kapur, Shitij ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BAR ILAN UNIVERSITY   (Israel)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL TRIAL (TOPIC); COMMUNITY ASSESSMENT; DEPRESSION; DISEASE ASSOCIATION; EDITORIAL; HUMAN; ITALY; MOTIVATION; NEGATIVE SYNDROME; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; REWARD; STUDY DESIGN; TREATMENT DURATION; TREATMENT PLANNING;

ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; SCHIZOPHRENIA;

EID: 84886259158     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2013.10.005     Document Type: Editorial

References (4)

1. Der-Avakian A., Markou A. The neurobiology of anhedonia and other reward-related deficits. Trends Neurosci. 2012, 35:68-77.
2. Kirkpatrick B., Fenton W.S., Carpenter W.T., Marder S.R. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr. Bull. 2006, 32:214-219.
3. Lieberman J.A., Dunbar G., Segreti A.C., Girgis R.R., Seoane F., Beaver J.S., Duan N., Hosford D.A. A randomized exploratory trial of an alpha-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia. Neuropsychopharmacology 2013, 38:968-975.
4. Marder S.R., Daniel D.G., Alphs L., Awad A.G., Keefe R.S. Methodological issues in negative symptom trials. Schizophr. Bull. 2011, 37:250-254.